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AbstrACt
Introduction Persistent physical symptoms (PPS), also 
known as medically unexplained symptoms are associated 
with profound physical disability, psychological distress 
and high healthcare costs. England’s annual National 
Health Service costs of attempting to diagnose and treat 
PPS amounts to approximately £3 billion. Current treatment 
relies on a positive diagnosis, life-style advice and drug 
therapy. However, many patients continue to suffer from 
ongoing symptoms and general practitioners (GPs) are 
challenged to find effective treatments. Training GPs in 
basic cognitive behavioural skills and providing self-help 
materials to patients could be useful, but availability in 
primary care settings is limited.
Methods and analysis A cluster randomised waiting list, 
controlled trial will be conducted to assess the feasibility 
of an integrated approach to care in general practice. 
Approximately 240 patients with PPS will be recruited 
from 8 to 12 GP practices in London. GP practices will 
be randomised to ‘integrated GP care plus treatment 
as usual’ or waiting list control. Integrated GP care plus 
treatment as usual will include GP training in cognitive 
behavioural skills, GP supervision and written and audio 
visual materials for both GPs and participants. The primary 
objectives will be assessment of trial and intervention 
feasibility. Secondary objectives will include estimating 
the intracluster correlation coefficient for potential 
outcome measures for cluster effects in a sample size 
calculation. Feasibility parameters and identification of 
suitable primary and secondary outcomes for future trial 
evaluations will be assessed prerandomisation and at 12 
and 24 weeks’ postrandomisation, using a mixed-methods 
approach.
Ethics and dissemination Ethical approval was granted 
by the Camberwell St Giles Ethics Committee. Results 
will be disseminated via peer-reviewed publications 
and conference presentations. This trial will inform 
researchers, clinicians, patients and healthcare providers 
about the feasibility and potential cost-effectiveness of an 
integrated approach to managing PPS in primary care.
trial registration number NCT02444520; Pre-results.
IntroduCtIon
Medically unexplained symptoms (MUS) 
are an umbrella term referring to persistent 
bodily symptoms, which cannot be adequately 
explained by organic pathology.1 MUS are 
highly prevalent with ~10%–49% of patients 
in primary care.2 3 MUS are associated with 
significant functional impairment, psycho-
logical distress and high healthcare costs.4–6 
Moreover, ~60% of patients have a comorbid 
psychiatric condition, including depression, 
anxiety and panic disorders.7–9 The National 
Health Service (NHS) in England is estimated 
strengths and limitations of this study
 ► Persistent Physical Symptoms  Reduction 
Intervention: a System Change  and Evaluation 
in Primary Care is a cluster, randomised, waiting 
list, controlled trial, designed to evaluate the ac-
ceptability and feasibility of an integrated general 
practitioner (GP) approach to care for adults with 
persistent physical symptoms (PPS).
 ►  A new transdiagnostic approach to managing pa-
tients with PPS in general practice was developed. 
This includes a Continuing Professional Development 
(CPD)  accredited basic cognitive behavioural skills 
training, as well as audio visual and written learn-
ing materials for GPs. Participants of GP practices 
randomised to ‘integrated GP care plus treatment as 
usual’ will receive tailored self-help materials.
 ►  This feasibility study is not powered to evaluate effi-
cacy or cost-effectiveness of integrated GP care but 
intends to identify suitable primary outcomes for an 
adequately powered future evaluation trial. 
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to spend approximately £3 billion each year attempting to 
diagnose and treat MUS, which represented ~10% of the 
total NHS expenditure in 2008–2009.10 
The term MUS is commonly used in healthcare and 
research. However, it has been argued that using the 
label persistent physical symptoms (PPS) may be more 
appropriate for a number of reasons. First, recent surveys 
indicated that people with such symptoms and healthy 
respondents preferred the term PPS, as it avoids mind-
body dualism and has cross-cultural relevance.11 12 Second, 
it includes symptoms associated with medically diag-
nosed long-term conditions, such as diabetes, rheuma-
toid arthritis and multiple sclerosis, which may present 
comorbidly with MUS. Third, it concurs with changes in 
the latest edition of the Diagnostic and Statistics Manual 
(DSM-5). The DSM-5 has consolidated previous terms 
including somatisation disorder, conversion disorder and 
hypochondriasis into a new diagnostic term—somatic 
symptom disorder. This refers to persistent (6 months) 
and clinically significant somatic complaints accompa-
nied by excessive and disproportionate health-related 
thoughts, feelings and behaviours regarding the symp-
toms.13 In this paper, we will use the term PPS to refer to 
MUS.
There is an accumulating body of evidence showing 
that cognitive behavioural interventions can reduce 
levels of symptoms and improve overall functioning in 
patients with PPS. Cognitive behavioural therapy (CBT) 
has demonstrated both short-term and long-term effi-
cacy with small to medium effect sizes for PPS.14 15 Larger 
treatment effects have been reported for specific PPS 
syndromes, including non-cardiac chest pain16 17 and irri-
table bowel syndrome.18–20
Research indicates that the way healthcare professionals 
deliver interventions and offer treatment to patients with 
PPS significantly affects health outcomes. For instance, 
a previous randomised controlled trial (RCT) evaluated 
the effectiveness of an integrated approach in treating 
women with chronic pelvic pain in secondary care. This 
involved an assessment of pain sensation, nociception, 
pain suffering and pain behaviour, followed by a discus-
sion about possible physical, psychological, dietary and 
environmental contributions plus physiotherapy, versus 
routine laparoscopy. The findings revealed that the 
integrated approach was significantly more effective in 
reducing pelvic pain compared with routine laparoscopy.21
Evidence supporting the efficacy of psychopharma-
cological interventions for PPS is less clear. A previous 
Cochrane review on pharmacological interventions 
found low-quality evidence for the use of new-generation 
antidepressants. No evidence was found for other psycho-
tropic drugs, including tricyclic antidepressants and anti-
psychotics.22 This suggests the need for further research 
investigating the effectiveness of non-pharmacological 
treatments in managing PPS, including psychosocial 
interventions.
General practitioners (GPs) play a major role in identi-
fying and managing patients with PPS. The Royal College 
of General Practitioners emphasise the importance of 
GPs in helping patients with PPS to make sense of their 
symptoms by adopting a biopsychosocial approach to 
treatment.23 A previous randomised parallel group pilot 
trial investigated the feasibility (ie, recruitment, retention 
and acceptability) of implementing a primary care symp-
toms clinic for patients with PPS.24 The symptoms clinic 
comprised a structured set of consultations delivered by 
a specially trained GP with a strong interest in PPS. The 
intervention included exploring potential biological mech-
anisms underlying the PPS condition, empathetic support 
and training patients in symptom management (ie, medi-
cation or cognitive behavioural techniques). The results 
indicated that the symptoms clinic was acceptable to the 
majority of patients randomised to the intervention group 
and may have the potential to generate clinically significant 
benefits. However, this pilot study did not assess feasibility 
parameters referring to GPs’ willingness to participate in 
the study and undergo specialised psychological training. 
Moreover, the intervention was carried out by only one GP, 
raising questions about the generalisability of the study.
Managing patients with PPS can be highly challenging 
in general practice. Although GPs recognise the treatment 
of PPS as a responsibility of primary care, previous studies 
show that GPs often feel powerless, frustrated and help-
less when encountering these patients.25 26 One possible 
explanation for this is an epistemological incongruence 
between taught ideal biomedical models of disease, and 
the reality of meeting patients presenting with subjective 
PPS, which cannot be fully explained by organic causes.26 
Furthermore, GPs frequently report that factors such as 
time constraints and the lack of psychological training 
prevents them from effectively addressing patients’ 
psychosocial needs and developing appropriate doctor–
patient communication skills.25
Taken together, there are four strands of evidence:
1. Psychological interventions may help patients with 
long-standing PPS.
2. The way in which investigations are carried out and of-
fered to patients with PPS affects health outcomes and 
service costs.
3. Psychopharmacological interventions (ie, antidepres-
sants) have shown no or only small effects on alleviat-
ing PPS.
4. GPs often feel helpless and ill-equipped to manage pa-
tients with PPS.
rEsEArCh objECtIvEs
This paper presents a study protocol for the Persistent 
Physical Symptoms Reduction Intervention: a System 
Change and Evaluation in Primary Care (PRINCE 
Primary) trial, which aims to assess the acceptability and 
feasibility of an integrated care approach in managing 
adult patients with PPS in primary care. Commissioning 
Support for London piloted an integrated service model 
for PPS, which largely focused on commissioning and 
cost saving.27 We will build on this pilot study by
 o
n
 5 August 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025513 on 23 July 2019. Downloaded from 
3Patel M, et al. BMJ Open 2019;9:e025513. doi:10.1136/bmjopen-2018-025513
Open access
1. Assessing the feasibility of trialling a new integrated 
approach towards the management of patients in pri-
mary care, using robust methods, namely a cluster ran-
domised waiting list, controlled trial.
2. Estimating the intracluster correlation coefficient for 
potential outcome measures for cluster effects in a 
sample size calculation.
3. Measuring patient satisfaction and patient-reported 
outcomes.
4. Including a broad range of patient groups in primary 
care, including those with non-cardiac chest pain, diz-
ziness and fibromyalgia.
5. Identifying suitable primary outcome measures for a 
future trial evaluation.
MEthods And AnAlysIs
study design
Two arm cluster randomised waiting list, controlled trial.
MEthod
Approximately 240 patients with PPS will be recruited 
from 8 to 12 GP practices. These GP practices will be 
randomised to either ‘integrated GP care plus treatment 
as usual’ or waiting list control. GP practices randomised to 
integrated GP care plus treatment as usual will include (1) 
GP training in cognitive behavioural techniques, (2) GP 
supervision, (3) audio visual material for GPs and (4) self-
help materials for participants. GP practices randomised 
to the waiting list control arm will continue with treat-
ment as usual. The waiting list control arm will be crossed 
over at 28 weeks to give 4 weeks to collect measures. This 
will not be part of the RCT but will contribute to a sepa-
rate long-term follow-up. A selection of feasibility param-
eters will be investigated prerandomisation. In addition, 
to identify suitable primary and secondary outcomes for 
future trial evaluations measures will be completed at 12 
and 24 weeks. GPs who attend the offer of GP training will 
complete measures pre and post GP training.
setting
GP practices and participants will be recruited from South 
London, England. GP training will take place at GP prac-
tices. Training will be delivered by clinicians based within 
King’s Health Partners.
study population
GP practices/GPs
GP practices within South London which fulfil the 
following eligibility criteria will be recruited into the 
study.
1. At least 50% of GPs within the practice express an in-
terest in completing the training workshop.
2. The practice manager, partner or other authorised in-
dividual is able to give consent for the practice to take 
part in the study.
3. The practice is not at risk of closure within the next 
year.
Patients
Patients who fit the eligibility criteria will be invited to 
take part in the study. Patients will be considered eligible 
for inclusion in this study if they fulfil all the following 
criteria;
1. Have a PPS (which is medically unexplained).
2. Are ≥18 and ≤65 years old.
3. Are registered with a GP practice in South London 
that has consented to taking part in PRINCE Primary.
4. Have had six or more consultations in the last year 
(not necessarily for the same symptom or directly re-
lated to PPS).
5. Have given written informed consent, provided base-
line data before randomisation and can speak and 
read English at a level adequate for participation in 
the trial.
Patients will be excluded from the study if the patient 
has
1. Active psychosis.
2. Drug or alcohol addiction as indicated in the patient’s 
medical notes.
3. Current benzodiazepine use exceeding the equivalent 
of 10 mg diazepam per day.
4. Had any psychotherapy treatment within the last year 
(not inclusive of general visits from community psychi-
atric teams).
5. Dissociative seizures.
6. If they are at imminent risk of self-harm, after psychiat-
ric/psychological assessment.
7. Taking part in the PRINCE Secondary study or 
the Assessing Cognitive behavioural Therapy in 
Irritable Bowel (ACTIB)  study.28
recruitment
GP practice recruitment
Invitation letters will be sent out to GP practices located 
in South London. If a GP practice is interested, it will 
be asked to contact the research team for further infor-
mation. GP practices that fit the eligibility criteria will 
be enrolled onto the study after providing consent to 
participate.
Patient recruitment
GP informatics (ie, EMIS Web) will be used to iden-
tify potential patients with PPS from GP practices that 
agreed to participate in the study. Prior to the study, the 
trial team liaised with GPs to ensure that the search crite-
rion intended to be uploaded onto EMIS Web included 
a range of PPS as well as incorporating elements of 
the trial’s eligibility criteria. For those patients identi-
fied in the search, the GP practice administration team 
will send information packs regarding the study and 
patients will be asked to reply to say whether they are 
interested or not interested in being contacted by the 
research team. Patients who express an interest will be 
contacted.
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study procedure
Patients who give their consent to be contacted will 
be further screened and checked for eligibility by the 
research team. If the research team is unsure about their 
diagnosis, they will contact their GP and ask for confir-
mation. To formally enrol, patients will be required 
to complete and return a signed consent form. Once 
consent is obtained, a baseline questionnaire pack will be 
sent to participants 4 weeks prior to a prespecified rando-
misation date. If participants complete the questionnaire 
pack before this date they will be fully eligible to take part 
in the study. Participants will be fully informed that if they 
do not complete the baseline pack before the randomisa-
tion date they will not be able to participate in the study. 
GP practices will be randomised on the prespecified date 
to one of two arms: integrated GP care plus treatment 
as usual or waiting list control (please see figure 1 and 
section on planned intervention for more details). Partic-
ipants of GP practices randomised to integrated GP care 
plus treatment as usual should be offered the self-help 
material within 1 week of randomisation and GP’s should 
be offered the training within 2 weeks of randomisation. 
GP practices randomised to the waiting list control arm 
will continue with treatment as usual until they are crossed 
over at 28 weeks. Based on these timeframes, a training 
date for all GP practices will be scheduled in advance. 
However, GP practices will be fully informed that the 
GP training session is dependent on the randomisation 
outcome, that is, only GP practices randomised to inte-
grated GP care will be offered the GP training. Once 
randomisation is completed both GP practices and partic-
ipants will be informed of the outcome and this will be 
week 0 and considered the anchor point for this trial for 
all the participants. Measures will subsequently be taken 
at 12 and 24 weeks.
The recruitment and study procedures will enable us 
to investigate a selection of feasibility parameters preran-
domisation and identify suitable primary and secondary 
outcomes for future trial evaluations. See figure 1 for a 
flow diagram showing the study procedure.
randomisation
Randomisation of the GP practice clusters will take 
place following recruitment and baseline assessments 
of patients within each GP practice. The randomisation 
method will be stratified randomisation at the level of 
the cluster (ie, GP practice). The randomisation will be 
stratified by size of GP practice (≤6000 registered patients 
or >6000 registered patients). GP practice randomisation 
will occur in pairs; two GP practices will be randomised at 
the same time with one being randomised to the waiting 
list control and the other being randomised to integrated 
GP care plus treatment as usual. Within strata (large or 
small practices) blocking is used to ensure that numbers 
allocated to either trial arm balance after each block. 
To avoid being able to predict the allocation of a GP 
practice, practices are randomised as pairs rather than 
sequentially. This ensures that forthcoming allocations 
cannot be predicted. Participants will have 4 weeks prior 
to randomisation to complete the baseline questionnaire 
pack. GP practice randomisation will be coordinated by 
an independent randomisation service at the United 
Kingdom Clinical Research Collaboration (UKCRC) 
registered King’s Clinical Trials Unit (KCTU).
blinding
Patients and GPs will not be blind to treatment alloca-
tion due to the nature of the trial (ie, therapy trial). The 
trial team member responsible for treatment allocation 
will be unblind. All outcome data are based on self-report 
and will be collected either by post or email. The research 
assistant(s) responsible for contacting participants who 
have not returned or completed follow-up questionnaires 
will be unblind. Moreover, the Data Monitoring and 
Ethics Committee (DMEC) research workers and trial 
statisticians will remain blind to treatment allocation. If 
unblinding is deemed to be necessary, the trial manager 
will use the system for emergency unblinding through the 
DMEC.
Planned intervention: integrated GP care plus treatment as 
usual
Our proposal seeks to develop new care pathways for 
patients with PPS.
The intervention integrated GP care plus treatment as 
usual will include:
Figure 1 Flow diagram of the study procedure about 
here. GP, general practitioner; R&D, Research and 
Development; RCT, randomised controlled trial.  
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1. GP training in utilising cognitive behavioural skills 
during 10 min consultations.
2. GP supervision.
3. Audio visual and written materials/guidelines for GP’s.
4. Written self-help materials for participants.
5. Animation to illustrate the approach.
6. Integrated case management discussion prior to sec-
ondary care referral. GPs will be encouraged to consult 
with a colleague before making a referral.
GP training
GP training will be delivered at GP practices by clinicians 
based within King’s Health Partners. To inform our deci-
sion about length of training, we discussed options with 
the GP’s and offered them anything from 1 hour to 1 day 
training in behaviour change skills. Most reported that 
they could spare up to 90 min as a group given their other 
commitments. For this reason, this is what we settled on. 
The session will involve a lecture, a role-play demon-
strating engagement of a patient in a dialogue which 
focuses on a behaviour change technique and discussion. 
The specific content of the session will include back-
ground information about PPS and a three systems model 
of understanding how symptoms might be perpetuated 
regardless of cause. The link between symptoms, cogni-
tions and behaviour will be described. The emphasis will 
be on engagement skills and behaviour change interven-
tions, not cognitive re-structuring, as this is more realistic 
for GP’s with limited time. More specifically, we will focus 
on techniques that improve sleep routines and the uptake 
of meaningful activities. In addition, we will demonstrate 
ways of negotiating the setting of goals that the indi-
vidual values, as homework. We will ask GP’s to use these 
skills and techniques in their consultations. We will not 
be encouraging the GP to see the participants for addi-
tional consultations. GPs will therefore use the approach 
during routine rather than study-specific consultations. 
To ensure that GPs are aware of which participants are 
taking part in PRINCE Primary we will upload a file note 
on the GP practice database for every patient who partic-
ipates. This means that if a participant has an appoint-
ment, the GP will be aware that they are participating in 
this study. GPs will be provided with study-specific guid-
ance on how to change the nature of consultations. Guid-
ance notes and supporting manuals/documentation will 
be written which are potentially sustainable and suitable 
for use in other NHS settings. Information will be tailored 
to the needs of the patient and will be focused on a range 
of clinical conditions. Examples include low back pain, 
dizziness and headaches.
A list of helpful responses in the consultation with 
patients will be provided. The training will be assessed 
(before and after) in terms of knowledge of PPS and 
confidence in diagnosing and managing these symptoms. 
Knowledge will be assessed via 10 true and false questions 
referring to the content of the training. GPs will also be 
asked to rate their confidence in working with patients 
with persistent symptoms by responding to a series of 
prespecified questions, using a Likert scale ranging from 
1 (not at all confident) to 7 (very confident). Satisfaction 
with training will be assessed after the training. Open-
ended questions will be used to elicit feedback about the 
workshops. Optional supervision (individual face-to-face, 
Skype/phone and/or group supervision) will be provided 
to GPs who request additional support. We will assess the 
uptake of this. Hand-outs will be available for GPs to give 
to participants. These will be reviewed for ease of reading 
by service users before the trial starts.
To summarise we have drawn on Lee David’s approach 
to GP education29 and our training will include:
1. How to make use of the cognitive behavioural model 
in their consultations.
2. How to overcome barriers to using this approach.
3. How to develop their consultation skills.
4. How to use a three systems model to examine relation-
ships between symptoms, thoughts and behaviour.
5. How to set an agenda and homework.
6. How to develop a partnership.
7. How to set some behavioural goals.
8. How to facilitate the patient in problem solving.
As this intervention does not encourage extra consul-
tations, we recruited frequent attenders based on the 
likelihood that they are more likely to visit their GP. 
We will also send participants booklets as we cannot 
be certain that they will visit their GP after GP training 
has taken place (ie, we are not just providing GPs with 
materials we are also providing self-help materials for 
participants).
Participant information booklets
Participants of GP practices randomised to integrated 
GP care plus treatment as usual will be offered a series 
of booklets based on cognitive behavioural principles 
via the post. These include (1) an introduction to PPS, 
(2) how to juggle activities, (3) improving sleep, (4) 
living with uncertainty, (5) emotional well-being and 
(6) goal setting. Participants will also be sent symptom 
booklets that include information about their primary 
symptoms. They will also have access to an animation 
describing a patient’s experience with chronic pain, via 
a website set up specifically for the PRINCE Primary 
trial.
Waiting list control: treatment as usual
GP practices randomised to the waiting list control will 
not be offered ‘integrated GP care’. Participants of GP 
practices randomised to the waiting list control arm will 
continue with treatment as usual. Treatment as usual is 
defined as the continuation of standard GP medical care 
for PPS, including usual GP follow-up and pharmacolog-
ical treatment. The GP practices in the waiting list control 
arm will be crossed over and offered integrated GP care 
plus treatment as usual. The cross over will be at 28 weeks 
to give 4 weeks to collect measures. However, this will not 
be part of the RCT.
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Feasibility parameters, measures and data collection time-
points
The aim of this study is to assess the feasibility of conducting 
a future evaluation trial to assess a new systems approach 
to PPS in general practice. Tables 1 and 2 provide an over-
view of data collection time-points. Based on the National 
Institute for Health Research's (NIHR) definition of a 
feasibility study,30 the PRINCE Primary trial will assess the 
following feasibility parameters:
1. Feasibility parameters:
a. Willingness of GP practices to be contacted about 
PRINCE Primary (number of GP practices respond-
ing out of GP practices approached).
b. Willingness of GP practices to consent and be ran-
domised (number of GP practices consenting to 
participate out of GP practices that responded with 
an interest to participate).
c. Availability of data needed and the usefulness and 
limitations of the general practice databases (num-
ber of patients identified using GP informatics 
Table 1 Overview of participant assessment moments and outcome measurements
Instrument
Pre 
randomisation Baseline 12 weeks 24 weeks
Feasibility parameters
  Interest of patients to be contacted about the study x
  Rate of eligible trial participants x
  Willingness of patients to consent to participate in 
PRINCE Primary
  Willingness of participants to complete baseline 
measures before randomisation
x
  Participants follow-up rates to questionnaires per group x x
Measures to identify suitable primary outcomes
  Psychosocial functioning WASAS x x x
  Physical symptoms PHQ-15 x x x
  Psychological distress PHQ-9 x x x
  Global outcome CGI x x
  Service use CSRI and 
EQ-5D-5L
x x
Potential mediators
  Treatment outcome CBRQ x x x
CBRQ, Cognitive Behavioural Responses Questionnaire; CGI, Clinical Global Impression; CSRI, Client Service Receipt Inventory; EQ-5D-
5L, EuroQol 5 Level; PHQ 9, Patient Health Questionnaire 9; PHQ-15, Patient Health Questionnaire 15; PRINCE Primary, Persistent Physical 
Symptoms Reduction Intervention: a System Change and Evaluation in Primary Care; WSAS, Work and Social Adjustment Scale. 
Table 2 Overview of GP’s/GP practices assessment moments and outcome measurements
Outcomes Instrument Prerandomisation
Pre-
training Post-training
Feasibility parameters
  Willingness of GP practices to be contacted about PRINCE 
Primary
x
  Willingness of GP practices to consent and be randomised x
  Availability of data needed and the usefulness and 
limitations of the general practice databases
x
  Interest of GPs to attend the GP training (intervention arm 
only)
x
GP training outcomes
  Knowledge and confidence Self-report x x
GPs, general practitioners; PRINCE Primary, Persistent Physical Symptoms Reduction Intervention: a System Change Evaluation in Primary 
Care.
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(search algorithm) out of patients registered with 
the GP practice).
d. Interest of patients to be contacted about the study 
(number of patients responding out of patients 
identified via the search algorithm).
e. Rate of eligible participants (number of patients 
meeting the eligibility criteria out of patients who 
responded with an interest to participate).
f. Willingness of patients to consent to participate in 
PRINCE Primary (number of patients consenting 
to participate out of patients who met the eligibility 
criteria).
g. Willingness of participants to complete baseline 
measures before randomisation (number of partic-
ipants sending baseline forms back out of partici-
pants that provided consent).
h. Interest of GPs to attend the GP training (interven-
tion arm only): (number of GPs attending the GP 
training out of number of GPs working at the GP 
practices offering training).
i. Participants follow-up rates to questionnaires per 
group (number of participants completing ques-
tionnaire packs at 12 and 24 weeks, respectively, out 
participants randomised).
2. Measures to identify suitable primary and secondary 
outcomes for future trial evaluations:
a. Psychosocial functioning: we will use the 5-item Work 
and Social Adjustment Scale (WSAS)31 to measure 
patients’ own perceptions of the impact of PPS on 
their functioning in terms of work, home manage-
ment, social leisure and private leisure activities, 
and close relationships.
b. Physical symptoms: we will measure the number of 
symptoms with the PHQ-1532 derived from the Pa-
tient Health Questionnaire which reflects DSM-IV 
diagnoses.
c. Psychological distress: mood will be assessed using the 
9-item PHQ.33
d. Global outcome: the adapted Clinical Global Impres-
sion34 change score yields a self-rated global meas-
ure of change and has been used in previous trials 
of CBT interventions.
e. Satisfaction: we will measure patients’ self-rated satis-
faction of the intervention via qualitative interviews 
(ie, thematic analysis).
f. Cost effectiveness (service): health service use (including 
hospital attendances and admissions, GP contacts), 
informal care, lost work time and financial benefits 
will be measured via the self-report Client Service Re-
ceipt Inventory35 and the EuroQol-5 Dimension (EQ-
5D).36 GP medical records will be used as an objective 
measure to assess the number of consultations and 
medical examinations patients received.
3. Process measures: the Cognitive Behavioural Respons-
es Questionnaire37 will be used to assess potential 
mechanisms of change.
4. GPs’ knowledge and confidence: GP training will be 
evaluated for knowledge, skills and confidence using 
self-reported measures. GPs who attend the offer of GP 
training will complete this pre and post GP training.
Qualitative component
Participants who consented to participate in a semi-
structured interview (~45 min) will be contacted after 
28 weeks to give 4 weeks’ to provide self-report  measures. 
If the participant is still interested a time and date will be 
arranged to conduct the interview either via telephone or 
face to face.
The aim of the qualitative interview will be to discuss 
the participant’s experiences and opinions of the inter-
vention, in particular (1) what they thought of the inter-
vention, (2) how useful they found the resources and 
(3) whether they perceived any differences in treatment 
approach during their GP consultation. Interviews will 
be audio recorded and transcribed by members of the 
research team using thematic analysis.
GP’s will also be invited to participate in a semistruc-
tured interview (group/individual). The aim of the inter-
view will be to discuss GPs experiences of implementing 
the intervention as well as discussing any suggestions on 
how the intervention could be improved. Interviews will 
be audio recorded and transcribed by members of the 
research team using thematic analysis.
data collection plan: retention
Retention rates will be maximised by providing partici-
pants with the option of completing questionnaires via 
post, telephone or email. Furthermore, thank you cards 
will also be sent at various stages of the trial.
Proposed sample size
A selection of 8–12 GP practices stratified by size 
(<6000 or >6000) (clusters) will be recruited, with an 
expected patient sample size of 240. This would mean 
that 120 patients will receive the integrated GP care by 
24 weeks and will complete measures. As this trial is a 
feasibility study, no formal power calculation has been 
carried out. Instead, the number of GP practices was 
chosen, such that we have sufficient replicates to estimate 
feasibility parameters at the practice level.
data management
Data will be collected on paper source data worksheets. 
Data will then be entered onto the InferMed MACRO 
online data entry system, on a study-specific data-
base designed and hosted at the KCTU. The system is 
compliant with Good Clinical Practice and  Title 21 Part 
11 of the Code of Federal Regulations (CFR) that estab-
lishes the United States Food and Drug Administration 
(FDA) regulations on electronic records and electronic 
signatures (FDA 21 CFR Part 11). Data exports will be 
provided to the trial statistician on request.
The web-based randomisation system will maintain 
an accurate record of randomisations and data can be 
exported from this system for reports. Postrandomisation 
data can be readily extracted from the MACRO trial data-
base for the preparation of DMEC reports and a front-end 
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search function is available to support data checking and 
cleaning.
Central data entry and data cleaning will be under-
taken by a designated research worker. Major issues in 
staff training or data quality will be raised with the trial 
manager, who will perform source data checking against 
the data collection forms. Discrepancies can be raised in 
the system for resolution by site staff. Source data verifi-
cation will be recorded on the system and any changes 
to data subsequent to verification will automatically 
generate an alert in the system. Individual user access to 
the InferMed MACRO system will be co-ordinated via the 
trial manager, who will submit requests to the KCTU. No 
direct requests from sites will be accepted.
The chief investigator will act as custodian for the trial 
data. The following guidelines will be strictly adhered to 
(1) patient data will be pseudo-anonymised (allocation 
of a unique personal identification number) and (2) all 
pseudo-anonymised data will be stored on a password-pro-
tected computer. All trial data will be stored in line with 
the General Data Protection Regulation and archived in 
line with sponsor requirements. Consent forms and other 
paper records will be stored in swipe-card accessed offices 
in locked filing cabinets.
statistical analysis
A Consolidated Standards of Reporting Trials (CONSORT) 
diagram will be constructed including various feasi-
bility parameters: the number of eligible practices and 
patients, number of practices and patients agreeing to 
enter the trial, number of GP practices randomised, then 
by treatment arm: the number of patients continuing 
through the trial, the number withdrawing from the 
study at various time-points. The feasibility parameters 
will be estimated using the CONSORT diagram and will 
be presented as proportions accompanied by 95% CIs to 
provide a measure of estimator precision.
Inferential analyses will be used to estimate inter-
vention effects in terms of outcome variables. The 
formal statistical analyses will estimate the difference 
in mean outcomes between patients from GP practices 
randomised to integrated GP care plus treatment as usual 
and waiting list control by intention to treat at 12 and 
24 weeks’ follow-up. We will provide estimates of trial arm 
differences with associated 95% CIs and will also trans-
late these effects into standardised effects sizes to enable 
comparisons across measures and time-points. This infor-
mation can help the planning of a future evaluation trial 
by providing guidance as to promising outcome measures 
and likely effect sizes. No formal significance testing will 
be carried out. Standardised effect sizes will be calculated 
by dividing estimated mean differences by the respective 
baseline SDs. Analysis will be based on the intention-to-
treat principle and we plan to use linear mixed modelling 
with maximum likelihood estimation. A random effect 
for participant will be entered in the model to account for 
correlations between repeated measures. Additionally, a 
random effect for cluster will also be included to allow 
for correlations between patients within a practice. Bias 
in estimates of trial arm differences will be avoided by use 
of randomisation and blinding of the outcome assessors.
All efforts will be made to avoid missing baseline data 
(ie, requiring completion of baseline data before rando-
misation), but missing values will be imputed according 
to current recommendations.38 Missing scale item data 
will be handled as per questionnaire specific recommen-
dations. We will aim to support participating practices to 
minimise loss to follow-up by encouraging a number of 
approaches: adopting other evidence-based procedures 
for recruiting and maintaining participation in the study 
and encouraging patients to return outcome measures 
(eg, contacting people before sending out question-
naires, sending personalised cover letters using colour 
printing and keeping measures short in terms of comple-
tion time).39 40
health economics
The main objective of the health economic aspect of the 
feasibility study is to assess what services are being used 
and this will inform the collection of service use data in 
a full trial.
data monitoring
The Programme Management Group will be respon-
sible for ensuring the appropriate, effective and timely 
implementation of the study. The DMEC and Programme 
Steering Committee (PSC) have been formed as indepen-
dent committees to oversee the study. The committees 
will be responsible for the independent oversight of the 
progress of the trial, the investigation of serious adverse 
events (SAEs) and for determination of trial progress.
Procedures for recording and reporting sAEs
Adverse events are any clinical change, disease or disorder 
experienced by the participant during their participation 
in the trial, whether or not considered related to the use 
of treatments being studied in the trial. Any SAEs, serious 
adverse reaction (SAR) or suspected unexpected serious 
adverse reaction will be recorded by the research worker 
at 12 and 24 weeks’ postbaseline. An adverse event is 
defined as serious if it:
1. Results in death.
2. Is life-threatening (with an immediate not hypotheti-
cal risk of death at the time of the event).
3. Requires hospitalisation (but not including elective 
hospitalisation for pre-existing condition).
4. Results in a new persistent or new significant disability 
or incapacity defined as:
a. Severe=a significant deterioration in the partici-
pant’s ability to carry out their important activities 
of daily living (eg, employed person no longer able 
to work, caregiver no longer able to give care, ambu-
lant participant becoming bed bound).
b. Persistent=4 weeks’ continuous duration.
5. Any other important medical condition which, though 
not included in the above, may jeopardise the partici-
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pant and may require medical or surgical intervention 
to prevent one of the outcomes listed.
6. Any new episode of deliberate self-harm.
We will require two clinically trained scrutinisers 
to review all SAEs and reactions, independently from 
the trial team. They will be blind to the treatment 
group and will be required to establish whether events 
reported constituted SAEs. The scrutinisers would then 
be unblinded to treatment allocation so that they can 
then establish whether any SAEs were SARs to the system 
approach.
stopping rules
The trial may be prematurely discontinued by the sponsor 
or chief investigator on the basis of new safety informa-
tion or for other reasons given by the DMEC/PSC or 
Research Ethics Committee (REC) concerned. The trial 
may also be prematurely discontinued due to lack of 
recruitment or on advice from the PSC (if applicable), 
who will advise on whether to continue or discontinue 
the study and make a recommendation to the sponsor. If 
the study is prematurely discontinued, active participants 
will be informed and no further participant data will be 
collected.
Auditing
The investigator(s) will permit trial-related monitoring, 
audits and REC review by providing the sponsor(s) and 
REC direct access to source data and other documents. 
Monitoring of this study will be to ensure compliance 
with Good Clinical Practice and scientific integrity will be 
managed by the study team. The study will be compliant 
with the research governance framework and MRC Good 
Clinical Practice Guideline.41 We will institute a rigorous 
programme of quality control. The trial manager will be 
based at the Institute of Psychiatry, Psychology and Neuro-
science, King’s College London and line-managed and 
supervised by the chief investigator. The trial manager 
will prepare study specific standard operating procedures 
(SOPs) for the study. The trial manager will supervise a 
designated research worker to undertake data manage-
ment/cleaning, so that they can provide regular reports 
on data quality to the chief investigator and the other 
coapplicants. Quality assurance checks will be under-
taken by the trial team to monitor the level of missing 
data and timeliness of data entry and check for illogical 
or inconsistent data. The trial manager will monitor data 
collection procedures, ensure that study data entry proce-
dures are followed and undertake source data verification 
against the paper data collection forms. The trial statisti-
cians will be affiliated with KCTU, and will be responsible 
for producing DMEC reports, drafting of the statistical 
analysis plan and for carrying out primary analyses. We 
will ask the DMEC to take on this role of monitoring 
participating GP practices at recruitment. Our KCTU has 
SOPs that guide the trial statistician’s reporting to the 
DMEC.
Patient and public involvement
In the early stages of this study, we developed links with key 
stakeholders including patients with PPS, commissioners 
and a national charity. The first meeting entailed an open 
discussion to ensure that the trial was not burdensome for 
patients and to also gain a better understanding of what 
GP’s felt was possible. We continue to involve these stake-
holders during the study. Patients were not involved with 
the recruitment of participants into the study. Peer-re-
viewed results will be disseminated to participating GP 
practices and study participants.
EthICs And dIssEMInAtIon
Ethical and research governance approval
This feasibility study is funded by Guy’s and St Thomas’ 
Charity. Ethical approval has been granted by the Camber-
well St Giles Ethics Committee (Reference 15/LO/0057) 
and King’s College London and South London and 
Maudsley (SLaM) Hospital will act as sponsors for the 
research. The study will be managed via a central co-or-
dinating team. The study was also submitted to NHS 
Clinical Research Network, South London for research 
governance and approval was received on 13 April 2015.
Confidentiality
All patient data will be pseudo-anonymised. All pseu-
do-anonymised data will be stored on a password-pro-
tected computer. All trial data will be stored in line with 
the Data Protection Act. Consent forms and other paper 
records will be stored in locked filing cabinets within 
swipe-card access offices.
Insurance/indemnity
Standard procedures for insurance of University and 
NHS employees and sites, and NHS patients will apply.
dissemination policy
We anticipate that there will be different target audiences 
for our dissemination activities:
1. Professionals: we will disseminate findings to healthcare 
professionals (eg, rheumatologists/neurologists/cardi-
ologists, psychiatrists, GPs, nurses, psychologists, CBT 
therapists) via papers in high impact peer-reviewed 
journals and presentations at local, national and inter-
national scientific meetings. We will also disseminate 
findings via the recently established UK Functional 
Neurological Symptoms group. Findings will also be 
presented at the British Association of Behavioural and 
Cognitive Psychotherapies conference and GP confer-
ences within the UK. We will make available written 
materials and offer training workshops for other NHS 
clinical services, and at meetings if appropriate.
2. Service planners and commissioners: if our study is suc-
cessful, we anticipate that our findings will have rele-
vance for the provision of care for patients with PPS, 
and therefore we will disseminate our findings to those 
who plan and commission care for people with PPS.
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3. Voluntary sector: we will make our findings available to 
PPS charities, which already disseminate information 
on PPS. We will offer summaries of our findings to web-
sites for the public which already provide information 
on PPS and to charities offering information on other 
MUS but not currently PPS.
dIsCussIon
This cluster randomised waiting list, controlled trial aims to 
investigate the feasibility of an integrated GP care approach 
plus treatment as usual for patients with PPS in primary care 
versus waiting list control. The intervention primarily oper-
ates at the GP practice (cluster) level and hence a cluster 
randomised trial design is employed. This means GP prac-
tices randomised to integrated GP care plus treatment as 
usual will include (1) GP training in cognitive behavioural 
skills, (2) GP supervision, (3) audio visual material for GPs 
and (4) self-help materials for participants. GP practices 
randomised to the waiting list control arm will continue 
with treatment as usual (ie, GP practices will not be offered 
the intervention initially but will be crossed over and 
offered the intervention at 28 weeks to give 4 weeks’ time to 
collect measures). Cluster randomised trials can be subject 
to selection bias when patients are recruited after allocation 
of the intervention to the clusters (GP practices). Hence, 
our design ensures that patients are recruited before their 
GP practice is randomised so their decision to take part 
in the trial cannot be informed by knowledge of whether 
the GP practice receives the intervention. To avoid partici-
pants having to wait a long time only those who frequently 
attended their GP will be eligible to participate in this study 
(please see eligibility criteria). Patients will not be dropped 
if they are not seen by a trained GP as the integrated care 
approach also includes self-help materials for patients. This 
study aims to mimic a real-life setting in which a patient may 
not see the same GP on a regular basis.
Given the prevalence of PPS and their costs to health 
services, there is an urgent need to develop easily accessible 
and affordable treatments for this patient group. Although 
previous studies have examined the efficacy of CBT-based 
approaches in treating patients with PPS, most studies were 
conducted in secondary care and focused on specific condi-
tions.14 15 Taken together, evidence suggests positive effects 
of CBT-based group intervention on PPS. However, group 
interventions and bringing in secondary care healthcare 
professionals may not always be feasible and time efficient. 
The present trial attempts to address these challenges by 
evaluating the feasibility of training GPs in delivering 
behaviour change interventions in a 10 min consultation 
and providing patients with self-help materials.
There are limitations to this study. It is unlikely that all 
GPs will attend all of the training. However, we will orga-
nise the training at times that suit as many GPs as possible. 
We cannot be sure in any case that GPs will use the skills 
they may have acquired during the training. GPs consulta-
tions will not be recorded as GP’s themselves feel it is too 
burdensome. In order to mitigate these shortcomings, we 
will conduct semistructured qualitative interviews with a 
random selection of patients to assess whether they had 
seen a GP and whether they felt that a behaviour change 
intervention had been delivered.
In conclusion, this RCT aims to assess the feasibility of 
an integrated GP approach for treating patients with PPS. 
Based on the results of the study, a fully powered RCT will 
be considered in order to assess the clinical effectiveness 
of this approach in changing identified health-related 
outcomes.
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